HB 4081-2 (LC 208) 2/2/22 (SCT/ps)

Requested by Representative PRUSAK

PROPOSED AMENDMENTS TO HOUSE BILL 4081

On <u>page 1</u> of the printed bill, line 2, after "ORS" delete the rest of the line and insert "689.681, 689.682, 689.684, 689.686 and 743A.051; and prescribing".

4 After line 4, insert:

5 **"SECTION 1.** ORS 689.681 is amended to read:

6 "689.681. (1) As used in this section:

7 "(a) 'Kit' means a dose of naloxone or any other drug approved by the

8 United States Food and Drug Administration for the complete or par-

9 tial reversal of opioid overdose and the necessary medical supplies to ad-

10 minister the naloxone or other drug described in this paragraph.

11 "[(b) 'Opiate' means a narcotic drug that contains:]

12 "[(A) Opium;]

13 "[(B) Any chemical derivative of opium; or]

14 "[(C) Any synthetic or semisynthetic drug with opium-like effects.]

¹⁵ "[(c) 'Opiate overdose' means a medical condition that causes depressed ¹⁶ consciousness and mental functioning, decreased movement, depressed respir-¹⁷ atory function and the impairment of the vital functions as a result of ¹⁸ ingesting opiates in an amount larger than can be physically tolerated.]

"(b) 'Opioid' means a natural, synthetic or semisynthetic chemical
 that interacts with opioid receptors on nerve cells in the body and
 brain to reduce the intensity of pain signals and feelings of pain.

1 "(c) 'Opioid overdose' means a medical condition that causes de-2 pressed consciousness and mental functioning, decreased movement, 3 depressed respiratory function and the impairment of vital functions 4 as a result of ingesting opioids in an amount larger than can be 5 physically tolerated.

"(2) Notwithstanding any other provision of law, a pharmacy, a health 6 care professional or a pharmacist with prescription and dispensing privileges 7 or any other person designated by the State Board of Pharmacy by rule may 8 distribute and administer naloxone or any other drug approved by the 9 United States Food and Drug Administration for the complete or par-10 tial reversal of opioid overdose and distribute the necessary medical sup-11 plies to administer the naloxone or other drug described in this 12 subsection. The pharmacy, health care professional or pharmacist may also 13 distribute multiple kits to social service agencies under ORS 689.684 or to 14 other persons who work with individuals who have experienced an [opiate] 15 opioid overdose. The social services agencies or other persons may redis-16 tribute the kits to individuals likely to experience an [opiate] opioid over-17 dose or to family members of the individuals. 18

"(3) A person acting in good faith, if the act does not constitute wanton misconduct, is immune from civil liability for any act or omission of an act committed during the course of distributing and administering naloxone or other drug described in subsection (2) of this section and distributing under this section the necessary medical supplies to administer the naloxone or other drug described in subsection (2) of this section [under this section].".

In line 5, delete "1" and insert "2".

27 On page 2, after line 26, insert:

²⁸ "SECTION 3. ORS 689.684 is amended to read:

"689.684. (1) For purposes of this section, 'social services agency' includes,
but is not limited to, homeless shelters and crisis centers.

HB 4081-2 2/2/22 Proposed Amendments to HB 4081 "(2) A person may administer to an individual naloxone or any other
drug approved by the United States Food and Drug Administration for
the complete or partial reversal of opioid overdose that was not distributed to the person if:

5 "(a) The individual to whom the naloxone or other drug described in 6 this subsection is being administered appears to be experiencing an 7 [opiate] opioid overdose as defined in ORS 689.681; and

"(b) The person who administers the naloxone or other drug described
in this subsection is an employee of a social services agency or is trained
under rules adopted by the State Board of Education pursuant to ORS
339.869.

"(3) For the purposes of protecting public health and safety, the Oregon Health Authority may adopt rules for the administration of naloxone or other drug described in subsection (2) of this section by employees of a social services agency under this section.

¹⁶ "SECTION 4. ORS 689.686 is amended to read:

17 "689.686. (1) A retail or hospital outpatient pharmacy shall provide writ-18 ten notice in a conspicuous manner that naloxone or other drug approved 19 by the United States Food and Drug Administration for the complete 20 or partial reversal of opioid overdose and the necessary medical supplies 21 to administer naloxone or other drug described in this subsection are 22 available at the pharmacy.

"(2) The State Board of Pharmacy may adopt rules to carry out this sec-tion.".

In line 27, delete "2" and insert "5".

26 On page 3, delete lines 6 through 17 and insert:

"<u>SECTION 6.</u> The amendments to ORS 689.682 and 743A.051 by
sections 2 and 5 of this 2022 Act apply to prescriptions for opioids
written on or after the operative date specified in section 7 of this 2022
Act.

"SECTION 7. (1) The amendments to ORS 689.681, 689.682, 689.684,
689.686 and 743A.051 by sections 1 to 5 of this 2022 Act become operative
on January 1, 2023.

"(2) The State Board of Pharmacy may take any action before the 4 operative date specified in subsection (1) of this section that is neces- $\mathbf{5}$ sary to enable the board to exercise, on and after the operative date 6 specified in subsection (1) of this section, all of the duties, functions $\mathbf{7}$ and powers conferred on the board by the amendments to ORS 689.681, 8 689.682, 689.684, 689.686 and 743A.051 by sections 1 to 5 of this 2022 Act. 9 "SECTION 8. This 2022 Act takes effect on the 91st day after the 10 date on which the 2022 regular session of the Eighty-first Legislative 11 Assembly adjourns sine die.". 12

13